Hims & Hers Health (HIMS) Non-Current Assets (2019 - 2026)
Hims & Hers Health (HIMS) reported Non-Current Assets of $1.2 billion for Q1 2026, up 174.69% on a YoY basis from $444.7 million in Q1 2025, and down 11.92% sequentially from $1.4 billion in Q4 2025.
Hims & Hers Health (HIMS) Non-Current Assets (2019 - 2026) Analysis & Trends
Hims & Hers Health (HIMS) has 8 years of Non-Current Assets data on file, last reported at $1.2 billion in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Assets rose 174.69% year-over-year to $1.2 billion; the trailing twelve-month figure through Mar 2026 stood at $4.5 billion (up 269.81% YoY), and the FY2025 full-year result was $1.4 billion, up 344.99% from the prior year.
- Non-Current Assets fell to $1.2 billion in Q1 2026, from $1.4 billion in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $1.4 billion in Q3 2025 to a low of $149.4 million in Q3 2022.
- A 5-year average of $421.9 million and a median of $186.4 million in 2024 frame the typical range for Non-Current Assets.
- Peak annual rise in Non-Current Assets reached 2531.36% in 2022, while the deepest fall reached 0.62% in 2022.
- Tracing HIMS's Non-Current Assets over 5 years: stood at $149.7 million in 2022, then increased by 17.62% to $176.1 million in 2023, then surged by 76.97% to $311.7 million in 2024, then soared by 344.99% to $1.4 billion in 2025, then dropped by 11.92% to $1.2 billion in 2026.
- Business Quant data shows HIMS's Non-Current Assets at $1.2 billion in Q1 2026, $1.4 billion in Q4 2025, and $1.4 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | 36.78 Bn |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 26.33 Bn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 8.68 Bn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 79.20 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 3.84 Bn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | 18.82 Mn |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 25.92 Bn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 2.47 Bn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 9.64 Bn |
| 10 | Hims & Hers Health | 6.44 Bn | 5.69 Bn | 396.79 Mn | 1.22 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.22 Bn |
| Dec 31, 2025 | 1.39 Bn |
| Sep 30, 2025 | 1.39 Bn |
| Jun 30, 2025 | 522.02 Mn |
| Mar 31, 2025 | 444.75 Mn |
| Dec 31, 2024 | 311.71 Mn |
| Sep 30, 2024 | 275.89 Mn |
| Jun 30, 2024 | 189.58 Mn |
| Mar 31, 2024 | 186.37 Mn |
| Dec 31, 2023 | 176.13 Mn |
| Sep 30, 2023 | 163.65 Mn |
| Jun 30, 2023 | 155.24 Mn |
| Mar 31, 2023 | 150.78 Mn |
| Dec 31, 2022 | 149.75 Mn |
| Sep 30, 2022 | 149.37 Mn |
| Jun 30, 2022 | 149.48 Mn |
| Mar 31, 2022 | 150.09 Mn |
| Dec 31, 2021 | 150.68 Mn |
| Sep 30, 2021 | 145.84 Mn |
| Jun 30, 2021 | 11.36 Mn |